Psoriatic Arthritis - Pipeline Review, Q4 2010

Published by: Global Markets Direct

Published: Dec. 8, 2010 - 31 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Psoriatic Arthritis Overview
Therapeutics Development
An Overview of Pipeline Products for Psoriatic Arthritis
Psoriatic Arthritis Therapeutics under Development by Companies
Psoriatic Arthritis Therapeutics under Investigation by Universities/Institutes
Companies Involved in Psoriatic Arthritis Therapeutics Development
Novartis AG
Astellas Pharma Inc.
Pfizer Inc.
UCB Group
Celgene Corporation
PanGenetics B.V.
Universities/Institutes Involved in Psoriatic Arthritis Therapeutics Development
Psoriatic Arthritis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles - Companies
Apremilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cimzia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Psoriatic Arthritis - Featured News
Nov 11, 2010: Centocor Ortho Biotech Submits sBLA Application To FDA Seeking To Expand SIMPONI Label
Apr 24, 2008: Centocor Ortho Biotech Inc. Receives FDA Approval For Golimumab (SIMPONI)As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Psoriatic Arthritis, 2010
Products under Development for Psoriatic Arthritis - Comparative Analysis, 2010
Novartis AG, 2010
Astellas Pharma Inc., 2010
Pfizer Inc., 2010
UCB Group, 2010
Celgene Corporation, 2010
PanGenetics B.V., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
List of Figures
Number of Products under Development for Psoriatic Arthritis, 2010
Products under Development for Psoriatic Arthritis - Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010

Abstract

Psoriatic Arthritis - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Psoriatic Arthritis Pipeline Review, Q4 2010”, provides an overview of the Psoriatic Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis. “Psoriatic Arthritis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Psoriatic Arthritis.
  • A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Psoriatic Arthritis pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Psoriatic Arthritis therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.